Search

Displaying results 6081 - 6090 of 10000 in total
  1. Drug

    Bisoxatin

    go.drugbank.com/drugs/DB09219
    Approved

    Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine [L926]. … It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.

  2. Drug

    MUC1 Dendritic Cell Vaccine

    go.drugbank.com/drugs/DB05477
    Investigational

    Dendritic Cell (DC) Therapy is a newly emerging and potent form of immune therapy that amplifies the actions of the body's own immune system to help fight cancer, AIDS and other serious conditions. … The Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system

  3. Drug

    Epoetin delta

    go.drugbank.com/drugs/DB11624
    ApprovedWithdrawn

    Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.

  4. Drug

    ASI402

    go.drugbank.com/drugs/DB06373
    Investigational

    ASI402 is a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1. It is being investigated in cancers.

  5. Drug

    Glucagon

    go.drugbank.com/drugs/DB00040
    ApprovedInvestigational

    [L7640,L7643] Glucagon was granted FDA approval on 14 November 1960.[L7631] … Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.

  6. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after … another ROS1 inhibitor has failed rather than as an alternative first choice.

  7. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.

  8. Drug

    Molybdenum cofactor

    go.drugbank.com/drugs/DB02137
    Experimental

    Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage usually leading to death within months of birth, due to the lack of active sulfite oxidase.

  9. Drug

    Octamoxin

    go.drugbank.com/drugs/DB09249
    ApprovedWithdrawn

    This drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued. … Octamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class.

  10. Drug

    EP-2104R

    go.drugbank.com/drugs/DB05675
    Experimental

    EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly.